Drug Profile
Research programme: cellular therapeutics - Vycellix
Alternative Names: VY 202; VY 301; VY 401; VY OZ; VY X - Vycellix; VY-OZ platform - Vycelix; VY-X platform - VycelixLatest Information Update: 31 Oct 2023
Price :
$50
*
At a glance
- Originator Vycellix
- Class Cell therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
- No development reported Viral infections
Most Recent Events
- 31 Oct 2023 Preclinical development in cancer is ongoing in USA (Vycellix pipeline, October 2023)
- 31 Oct 2023 Vycellix announced the intention to submit IND applications for cancer in 2023 (Vycellix pipeline, October 2023)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)